fda tirzepatide shortage What is the latest update on the Compounded ban tirzepatide march 19th FDA Announced

Side effects are typically mild and manageable

doi: 10.3389/fphar.2023.975830 [DOI] [PMC free article] [PubMed] [Google Scholar] 60.Garca-Casares N, Gonzlez-Gonzlez G, de la Cruz-Cosme C, et al

These medications are prescription-only in the UK and require careful medical supervision, particularly when used in perimenopausal women who may be managing multiple health considerations

They market this second use of the drug under the name Weygovy

Medical eligibility requires absence of personal or family history of medullary thyroid cancer (MTC) and careful evaluation in those with chronic pancreatitis, severe kidney disease, or recent GI surgery